Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

174.11 5.63 +3.34%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

Repligen Corporation 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Item 1A, Risk Factors, against the 10-K filed Mar 14, 2025: 33 added · 23 removed · 55 modified; 1 with only figures updated